Cullinan Therapeutics, Inc. (CGEM) company profile
Close on Nov 13, 2026Market cap $661.57MP/E –Yield –
About Cullinan Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for autoimmune diseases and cancer. Its research and development efforts center on T cell engagers and targeted therapies. The company's pipeline includes CLN-978, a bispecific T cell engager being evaluated for autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, and Sjogren's disease. It is also developing velinotamig for autoimmune conditions, as well as CLN-049 for acute myeloid leukemia and myelodysplastic syndrome. In addition, the firm collaborates on zipalertinib, an oral targeted inhibitor for non-small cell lung cancer. Its prospective customers are patients with autoimmune diseases and cancers.
The company operates through research activities and clinical trials conducted globally, including trials in Europe and China. It relies on third parties for development functions and product manufacturing. Cullinan Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.
Summary of the business section of Cullinan Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cullinan Therapeutics, Inc.
- Headquarters
- Cambridge, MA
- Address
- One Main Street, Suite 1350 02142
- Phone
- (617) 410-4650
- Website
- cullinantherapeutics.com
- Employees
- 109, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- CGEM
- Exchange
- Nasdaq
- IPO date
- Jan 11, 2021
- Shares outstanding
- 64M, Jul 31, 2026
- Public float
- $442.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1789972
- CUSIP
- 230031106
- ISIN
- US2300311063
- FIGI
- BBG00HW2DGQ4
- Share class FIGI
- BBG00HW2DGR3
- EIN
- 81-3879991
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Nadim Ahmed | President and CEO, Director | 390,803 |
| Jennifer Michaelson | Chief Scientific Officer | 158,649 |
| Jacquelyn L. Sumer | Chief Legal Officer | 130,559 |
| Mary Kay Fenton | Chief Financial Officer | 127,921 |
| Jeffrey Alan Jones | Chief Medical Officer | 159,968 |
| Corrine Savill | Chief Business Officer | 240,990 |
| Andrew R. Allen | Director | – |
| Mary Thistle | Director | – |
| Stephen W. Webster | Director | – |
| David D. Meek | Director | – |
| Anthony Rosenberg | Director | 45,002 |
| Mittie Doyle | Director | – |
| Anne-Marie Martin | Director | – |
| David P. Ryan | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $5.10M | $2.33M | $2.15M | $98 | – |
| FY2024 | $7.68M | $8.90M | $3.84M | $115 | – |
| FY2023 | $4.01M | -$184.88K | $2.31M | $96590 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Nadim Ahmed President and Chief Executive Officer | $698.48K | $1.70M | $2.23M | $419.09K | $50.70K | $5.10M | -34% |
| Jeffrey Jones, M.D. Chief Medical Officer | $529.80K | $612.95K | $806.85K | $218.28K | $53.70K | $2.22M | -34% |
| Mary Kay Fenton Chief Financial Officer | $512.33K | $565.80K | $744.78K | $211.90K | $44.03K | $2.08M | -50% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 11, 2021
- Offer price
- $21.00
- Securities offered
- 11,900,000
- Gross proceeds
- $249.90M
- Exchange
- Nasdaq
- First trading day
- Jan 8, 2021
- First-day close
- $29.91+42.4%
- Lock-up ends (est.)
- Jul 7, 2021
“The initial public offering price is $21.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 109 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 2, 2024 | Name change | Name changed from Cullinan Oncology, Inc. to Cullinan Therapeutics, Inc. |
| Jan 8, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 27, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 22, 2021 | Name change | Name changed from Cullinan Management, Inc. to Cullinan Oncology, Inc. |
| Jan 11, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 6, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jan 6, 2021 | Name change | Name changed from Cullinan Oncology, LLC to Cullinan Management, Inc. |
See a number that looks wrong?